Methotrexate pharmacokinetics and prognosis in osteosarcoma

Area of Science:

• Pharmacokinetics
• Oncology
• Pharmacodynamics

Background:

• High-dose methotrexate (HDMTX) is a key treatment for osteosarcoma.
• Understanding MTX pharmacokinetics is vital for optimizing treatment efficacy.
• Previous studies have explored MTX dosing but detailed pharmacokinetic-efficacy relationships require further analysis.

Purpose of the Study:

• To analyze the influence of methotrexate (MTX) pharmacokinetic parameters on the efficacy of high-dose MTX (HDMTX) in osteosarcoma.
• To determine the correlation between MTX serum levels and patient prognosis.
• To evaluate the impact of specific treatment modifications on MTX pharmacokinetics.

Main Methods:

• Retrospective analysis of MTX serum peak values and pharmacokinetic data from 198 patients across 1,703 treatment courses in COSS studies (COSS-80, COSS-82, COSS-86).
• Investigated correlation between MTX peak levels, area under the curve (AUC), and disease-free survival (DFS).
• Assessed the effects of concomitant cisplatin (DDP) and restricted hydration on MTX pharmacokinetics.

Main Results:

• A mean threshold peak MTX level of ≥1,000 mumol/L significantly correlated with improved prognosis in COSS-80 (18% vs. 64% 10-year DFS, P=.0001).
• Six courses of HDMTX achieving peak levels ≥1,000 mumol/L were sufficient for optimal DFS in COSS-80.
• Concomitant cisplatin (DDP) and restricted hydration (3 L/m²/24h) increased MTX peak levels and AUC, improving pharmacokinetic profiles.

Conclusions:

• MTX pharmacokinetics significantly influence the efficacy of HDMTX in osteosarcoma treatment.
• Individual dose adaptation to achieve a threshold peak serum level of ≥1,000 mumol/L may not be necessary with a fixed dose of 12 g MTX/m², restricted hydration, and DDP.
• Optimized hydration and DDP co-administration enhance MTX efficacy in osteosarcoma.